Quanterix Stock Price, News & Analysis

Kent Lake, holding approximately 7.5% of Quanterix (NASDAQ: QTRX) shares, has expressed strong opposition to Quanterix's recent $30 million convertible notes agreement with Akoya Biosciences (NASDAQ: AKYA).

The agreement, part of a broader merger deal, allows Akoya to sell convertible notes to Quanterix until July 2025, even if the merger is terminated. Kent Lake criticizes this as a 'backdoor financing' arrangement, highlighting that Akoya faces a 'near-term liquidity crisis' and arguing that Quanterix shareholders will be left with 'high-risk subordinated distressed debt'.

Kent Lake claims the Board violated fiduciary duties by not providing comprehensive disclosures on the bridge financing terms and lacking a fairness opinion. They urge shareholders to vote AGAINST both merger-related proposals.

Quanterix (NASDAQ: QTRX) has unveiled a new dried blood spot (DBS) extraction kit for their Simoa® assay platform at the AD/PD conference in Vienna. The innovative kit aims to revolutionize neurodegenerative disease testing by enabling biomarker measurement from dried blood spots, offering a more cost-effective and less invasive alternative to traditional venous blood draws.

The DBS extraction kit, developed in collaboration with the DROP-AD Project at the University of Gothenburg, includes buffers and sample preparation protocols. Validation studies demonstrated correlation rates of 0.75 to 0.86 between DBS samples and venous samples in simulated CSF testing using Simoa ALZpath p-Tau 217.

The company's Simoa® technology is being featured in over 80 posters and presentations at the conference, highlighting its impact on neurodegenerative disease research. This advancement aims to improve accessibility to biomarker testing, particularly in remote or resource- settings, and expand participation in Alzheimer's research among under-represented populations.

Tikvah Management , holding approximately 1.5% of Quanterix Corp. (QTRX) shares, has announced its intention to vote against the proposed merger with Akoya Biosciences (AKYA) at the upcoming Quanterix Special Meeting. As a significant investor since 2018, Tikvah opposes the merger citing three main concerns:

• Undervaluation of Quanterix shares in the proposed deal
• Expected significant reduction in company cash flow post-merger
• Quanterix's business superiority compared to Akoya's

Tikvah has noted that other investors have also publicly expressed opposition to the merger, though they maintain the right to change their position if significant new developments arise.

Sera Prognostics (Nasdaq: SERA) announced significant changes to its Board of Directors. Jeff Elliott, currently a senior advisor at Boston Consulting Group and board member of Quanterix , will join the board on March 20, 2025. Elliott brings extensive experience in corporate strategy, business operations, and commercializing molecular diagnostics, having previously served as CFO and COO at Exact Sciences.

The company also announced that Ryan Trimble will retire and step down as director on June 30, 2025, after 14 years of service. Additionally, Marcus Wilson will not seek re-election at the 2025 Annual Meeting of Stockholders. Both departures are part of the board's ongoing efforts to refresh its composition and expertise.

These changes come at a important time as Sera begins leveraging its recent PRIME study results to build market presence for its PreTRM® test, focusing on improving maternal and neonatal health through pregnancy biomarker information.

Quanterix (NASDAQ: QTRX) reported Q4 2024 financial results, marking its seventh consecutive quarter of double-digit revenue growth. Q4 revenue reached $35.2 million, up 11% year-over-year, with a GAAP gross margin of 63.0%. The company posted a net loss of $11.6 million.

Full-year 2024 revenue was $137.4 million, a 12% increase from 2022, with a net loss of $38.5 million. The company ended 2024 with $291.7 million in cash and equivalents.

Key developments include:

• Announced acquisition of Akoya Biosciences in an all-stock transaction, expected to close in Q2 2025
• Plans to launch Simoa ONE instrument by end of 2025
• Acquired EMISSION for bead manufacturing capabilities
• Received FDA Breakthrough Designation for LucentAD Complete test

For 2025, Quanterix projects standalone revenue of $140.0-146.0 million (2-6% growth) with gross margin of 59-63%.

Kent Lake PR , holding 7.47% of Quanterix (NASDAQ: QTRX) shares, has expressed strong opposition to the proposed merger with Akoya Biosciences (NASDAQ: AKYA). The investor raises critical concerns about the transaction, highlighting that over 82% of the combined company enterprise value would be allocated to Akoya shareholders, leaving less than 18% for Quanterix shareholders.

Kent Lake has nominated three independent candidates for Quanterix's Board of Directors and demands answers to key questions regarding: the disproportionate value distribution, Akoya's going concern issues, potential conflicts of interest involving board member Dr. Ivana Magovčević-Liebisch, material NIH funding risks, and the merger process where Quanterix was reportedly bidding against itself after other bidders withdrew due to concerns about Akoya's high cash burn and debt.

Quanterix (NASDAQ: QTRX) has scheduled its fourth quarter and full year 2024 financial results announcement for March 17, 2025. The company will release the results after market close, followed by a conference call at 4:30 p.m. E.T. on the same day.

Investors can participate in the live conference call by dialing 888-596-4144 or 646-968-2525 with Conference ID: 4306988. A live webcast will be available on the News & Events page in the Investors section of Quanterix's website, with the webcast replay remaining accessible for one year.

Kent Lake, holding 7.25% of Quanterix (NASDAQ: QTRX) shares, has issued a strong opposition to the proposed merger with Akoya Biosciences (NASDAQ: AKYA). The investor presentation highlights several concerns:

The deal values Akoya at nearly 5x higher than Quanterix despite Quanterix's superior market position, leading to a 40% decline in Quanterix's shares since announcement. The merger process revealed Quanterix as the sole bidder after other potential buyers withdrew due to concerns about Akoya's profitability and cash burn.

Key criticisms include: a proposed $30 million bridge financing to Akoya without clear shareholder approval, potential NIH funding cuts affecting Akoya's stability, and the deal's negative impact on Quanterix's promising Alzheimer's testing program. Kent Lake has nominated three independent candidates for Quanterix's 2025 Board election, arguing that abandoning the merger would create better shareholder value.

Quanterix (NASDAQ: QTRX) has reaffirmed the strategic benefits of its proposed acquisition of Akoya Biosciences, aimed at creating the first integrated solution for ultra-sensitive biomarker detection in blood and tissue. The merger will expand Quanterix's addressable market to $5 billion across neurology, immunology, and oncology, with an additional $10 billion opportunity in Alzheimer's Disease diagnostics.

The company projects $40 million in annual run-rate cost synergies by the end of 2026, with $20 million expected within the first year post-closing. Quanterix anticipates reaching $1 billion in revenue with 15% EBIT margins within five years after closing, with positive free cash flow expected by 2026.

The company also addressed nominations from Kent Lake PR for three board candidates, stating that Kent Lake's analysis contains flawed assumptions and inaccurate information. The transaction is expected to close in Q2 2025, pending shareholder approvals and closing conditions.